D URING THE ANALYSIS OF MISOprostol Ulcer Complications
Outcomes Safety Assessment (MU-COSA) trial an important outcome was identified involving nonsteroidal antiinflammatory drugs (NSAIDs) and gastrointestinal perforations. In this clinical trial, 8849 patients receiving a variety of NSAIDs were randomized to receive either misoprostol or placebo as a cytoprotective agent. Seven of the 4443 placebo patients (0.15%) developed a gastrointestinal perforation. In contrast, only one of the 4406 patients taking misoprostol developed a gastrointestinal perforation (P<0.02) (1) . These data suggest that NSAID use may be an important factor in the development of gastrointestinal perforation and that misoprostol may prevent these NSAID-induced perforations.
This descriptive study characterizes patients with gastrointestinal perforations admitted to the two major referral teaching hospitals in Edmonton, Alberta between January 1, 1989 and December 31, 1993. Patients who developed perforations while taking NSAIDs were compared with those taking acetylsalicylic acid (ASA), those taking both NSAIDs and ASA, and those taking neither NSAIDs nor ASA.
PATIENTS AND METHODS
Patients admitted to the University of Alberta Hospital and the Royal Alexandra Hospital between January 1, 1989 and December 31, 1993 for gastric, duodenal, intestinal and colonic perforations diagnosed by surgery and/or x-ray were considered eligible for the study. These two tertiary referral hospitals serve a population of approximately 1.5 million. Over the interval of the study there were 297,571 admissions to the two hospitals. Using a computerized search program, these admissions were screened to identify records that indicated a primary diagnosis of gastric ulcer perforation (International Classification of Diseases [ICD] 9-CM codes 531.1 to 531.6 except .3 and .4), duodenal ulcer (532.1 to 532.6 except .3 and .4), peptic ulcer site unspecified (533.1 to 533.6 except .3 and .4), gastrojejunal ulcer (534.1 to 534.6 except .3 and .4) and perforation of the colon and intestine (569.83). In the above ICD 9-CM coding .1 signifies acute with perforation, .2 signifies acute with hemorrhage and perforation, .3 signifies acute without mention of hemorrhage or perforation, .4 signifies chronic or unspecified without hemorrhage or perforation, .5 signifies chronic or unspecified with perforation and .6 signifies chronic or unspecified with hemorrhage and perforation.
This computerized record review identified 503 patient charts with the above ICD 9-CM codes. Each of these charts was manually reviewed systematically by a single researcher to document specific patient characteristics (Table 1) . Of the 503 patient charts, only 428 (0.144% of the total hospital admissions over the five-year study interval) had documented evidence of a gastrointestinal perforation (Figure 1 ). The remainder of the patient charts (75) were improperly coded, or contained no surgical or x-ray documentation of perforation.
To compare the proportions of two categories within a single study group, data were analyzed using a z test with the Yates correction for continuity.
To compare the distributions of two or more study groups within two or more categories, c 2 analysis was carried out. P values were determined using SigmaStat statistical software (Jandel Scientific Software, California) and deemed significantly different when P<0.05.
RESULTS
The 428 patients with documented perforations (Figure 1) (Figure 3 ). However, when the groups were examined individually there were two study groups with statistical differences between male:female ratios. The majority of the NSAID users were female (64%; 52 of 81) (P=0.028), while the majority of neither NSAID nor ASA users were male (58%; 176 of 305) (P=0.008). The group using ASA alone (P=0.409) and the group using both NSAIDs and ASA (P=0.789) did not demonstrate differences in female: male ratios. Age demographics: Figure 4 demonstrates that in the total study sample feProfil des patients sous AAS ou AINS hospitalisés pour perforation gastro-intestinale DONNÉES DE DÉPART : Lors d'un récent essai clinique, on a pu découvrir que les perforations gastro-intestinales survenaient à une fréquence de 0,15 % chez les patients traités par anti-inflammatoires non stéroïdiens (AINS) et qu'elles pouvaient être atténuées chez les patients à qui l'agent cytoprotecteur misoprostol était administré concomitamment. OBJECTIF : Identifier les caractéristiques des patients atteints de perforations gastro-intestinales admis dans deux grands centres hospitaliers universitaires d'Edmonton, en Alberta, entre le 1 er janvier 1989 et le 31 décembre 1993. MÉTHODES : Un programme de recherche informatisé a été utilisé afin de sélec-tionner les dossiers des patients renfermant des codes 9-CM de la classification internationale des maladies, et les patients ont été répartis entre quatre groupes selon les médicaments qui leur avaient été administrés : ceux qui prenaient des AINS, ceux qui prenaient de l'AAS, ceux qui prenaient les deux et ceux qui ne prenaient ni l'un ni l'autre. RÉSULTATS : Les caractéristiques significatives suivantes ont été identifiées chez les 428 patients admis pour perforations : seule une minorité d'entre eux (29 %) prenaient des AINS ou de l'AAS; les utilisateurs d'AINS étaient davantage des femmes, alors que ceux qui ne prenaient ni AINS ni AAS étaient davantage des hommes; les femmes étaient plus âgées que les hommes; les patients sous AINS, AAS ou les deux étaient plus souvent asymptomatiques lors de leur admission, en comparaison avec les sujets qui ne prenaient pas de tels médicaments; et les perforations des voies digestives hautes s'observaient plus souvent au duodénum qu'à l'estomac, alors que les perforations des voies digestives basses affectaient davantage le côlon que l'intestin grêle. CONCLUSIONS : Cette étude rétrospective dresse le profil du patient qui consulte à l'hôpital pour perforation gastro-intestinale. De plus, elle révèle que l'emploi d'AINS ou d'AAS altère significativement ce profil, comparativement aux cas où ni l'un ni l'autre de ces médicaments ne sont employés. male patients were significantly older (61±2 years) at the time of perforation than their male counterparts (56±2 years) (P=0.008). However, within each study group age differences between females and males did not reach statistical significance (Figure 4) . In contrast, when males were compared as a group, those using NSAIDs, ASA or both were older than those males taking neither drug (P=0.002). Similarly, when females were compared as a group, those using NSAIDs, ASA or both were older than those females taking neither drug (P=0.002). Symptoms at presentation: In the total study sample there was no difference between the proportion of patients with symptoms at clinical presentation (54%; 233 of 428) and those asymptomatic at clinical presentation (46%; 195 of 428) (P=0.121). However, when each study group was examined individually, patients taking neither NSAID nor ASA were more likely to be symptomatic (57%; 174 of 305) than asymptomatic (43%; 131 of 305) (P=0.021). In contrast, patients in the other three groups were just as likely to be symptomatic as asymptomatic at presentation (patients taking NSAIDs: 47% symptomatic [38 of 81] versus 53% asympto- ischemic colitis (8%), diverticular disease (6%), operative complications (4%) and trauma (2%) ( Table 3 ). In 12% of cases the cause of the non-NSAID/ASA perforation was not documented.
Diagnosis and therapy:
As shown in Table 4 surgical therapy was required in the vast majority of patients with perforations, regardless of study group. In addition, the use of NSAIDs, ASA or both before intestinal perforation did not significantly alter the duration of hospitalization or the interval spent in the intensive care unit. Mortality rate: In the total study sample, 19% of patients (81 of 428) presenting with an intestinal perforation died. Figure 6 shows the mortality rates for each study group. There was no statistical difference in the proportion of deaths between study groups. Of interest, the more distal the perforation, the higher the mortality rate. Seven of 22 patients with colonic perforations (32%) died, two of nine with small intestinal perforations (22%) died, three of 18 with stomach perforations (17%) died and two of 32 with duodenal perforation (6%) died. Unavailable information: Due to insufficient historical documentation a number of variables outlined in the initial study design (Table 1) were unobtainable. In particular, the dose and duration of ASA and NSAID use, comorbid conditions, and family and past history of peptic ulcer disease were poorly documented. DISCUSSION This descriptive study revealed that over a five-year interval 428 patients, representing 0.14% of the total number of admissions, presented with gastrointestinal perforations to the University of Alberta and Royal Alexandra Hospitals in Edmonton, Alberta. This perforation rate in patients using NSAIDs, ASA or both is identical to that previously identified (1) . In the present study, 29% of the total study group were taking NSAIDs, ASA or both (Figure 2) . This high rate of association with NSAID and/or ASA use greatly exceeds the 7 to 10% rate of NSAID prescription in the Alberta population at any given time (Alberta Blue Cross Physician Prescribing Data Base). This high percentage of NSAID and/or ASA use among patients with gastrointestinal perforation implies more than a casual association.
The most frequently used NSAIDs in patients with perforation were indomethacin and diclofenac ( Table  2 ), results that parallel those of a 1993 study at the University of Alberta Hospital (2). Furthermore, information from the Alberta Blue Cross Physician Prescribing Data Base indicates that the chance of a specific NSAID being associated with a patient presenting with perforations (Table 2 ) corresponds almost identically to the frequency with which that specific NSAID is prescribed. Thus, the association of a perforation with a specific NSAID likely relates to the frequency of its use rather than any specific NSAID-associated risk factor.
The fact that the majority of NSAID users were female (Figure 3 ) is likely attributable to the increased use of NSAIDs in the female population. Females are three times more likely than males to develop rheumatoid arthritis than males and to fill more NSAID prescriptions in all age groups (3). In contrast, men, being more likely to take ASA as effective therapy for primary and secondary prevention for myocardial infarction, made up the larger proportion of patients taking ASA ( Figure  3 ).
In the total study group, females (61±2 years) were significantly older than males at the time of perforation (56±2 years). Within male only and female only categories, those taking NSAIDs and/or ASA were older than those not taking any drug (Figure 4) . The reason for these differences remains unclear but may reflect a number of factors including increased longevity of females, increased frequency of the female population in accessing health care and the increase in diseases requiring NSAID or ASA therapy in the elderly (4).
Considering both age and sex statistics, the group most associated with NSAID-related perforations was elderly
women. An effective prophylactic medication that prevents NSAID-related perforations in this high risk group would be beneficial (3, 5) .
Patients who were taking neither drug before perforation were more likely to be symptomatic compared with patients who were on NSAIDs, ASA or both (P=0.021), which contrasts with the equal proportion of symptomatic and asymptomatic presentations in patients who develop gastrointestinal ulceration while on NSAIDs (6, 7) . The reason for this discrepancy remains to be determined but may relate to the analgesic effects of the medications.
In the total study population, perforations that occurred in the upper gastrointestinal tract were more likely to involve the duodenum than the stomach (P=0.035), and perforations that occurred in the lower gastrointestinal tract were more likely to involve the colon than the small bowel (P=0.049) ( Figure 5 ). In each study group this trend towards more frequent perforations in the duodenum and colon persisted, but did not reach statistical significance. The higher incidence of perforations in the duodenum of the upper gastrointestinal tract parallels the site and frequency of NSAID-and non-NSAID-induced ulceration (8, 9) . NSAID and/or ASA use did not increase the frequency of gastric or colonic perforations despite both drugs' predilection for causing gastric ulceration and for causing colonic mucosal injury in their sustained release formulations (9) .
CONCLUSIONS
This retrospective descriptive study outlines group characteristics of patients presenting to a referral hospital with a gastrointestinal perforation. Furthermore, it suggests that the use of NSAIDs, ASA or both significantly alters this profile compared with that in patients using neither NSAIDs nor ASA.
